• Explore /
  • Poster
  • / Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

Abstract Poster

Authors

Yelena Janjigian

Yelena Yuriy Janjigian

Memorial Sloan Kettering Cancer Center, New York, NY

Yelena Yuriy Janjigian , Antoine Adenis , Jean-Sebastien Aucoin , Carlo Barone , Narikazu Boku , Ian Chau , James M. Cleary , Kynan Feeney , Fabio Andre Franke , Markus Moehler , Enrique Luis Roca , Michael Schenker , Mingshun Li , Jaffer A. Ajani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Translational Research

Clinical Trial Registration Number

NCT02872116

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract TPS213)

DOI

10.1200/JCO.2017.35.4_suppl.TPS213

Abstract #

TPS213

Poster Bd #

N17

Abstract Disclosures

Similar Posters

First Author: Samuel J Klempner

First Author: Ryan Sugarman

First Author: Salah-Eddin Al-Batran

First Author: Markus H. Moehler